Funding Announcements

"Our next phase of growth will involve building international partnerships, growing the team, and appointing a scientific advisory committee to support the work of the main board."

"I've long been fascinated by how reversing mitochondrial dysfunction could arrest the progression of degenerative diseases, which place great burdens on patients and healthcare systems. This seed financing will enable us to advance MitoRx's first-in-class therapeutic pipeline. We are the first biotech to address dysfunction of sulfide-signalling, a fundamental part of life's energy systems. I'm also delighted to welcome Glyn to the team whose wealth of experience will be a great asset as we accelerate our novel pipeline of small molecule mitochondrial protective therapeutics towards the clinic."

"BioZeroc’s insight is rooted in nature, where microorganisms create extremely strong structures like coral. We use the power of cutting-edge biotechnology to optimise and scale up a similar bacterial process that binds together the aggregate, replacing the need for conventional cement altogether,"

"Since meeting Patrick and the Sano team, we have been consistently impressed with their unwavering purpose-led strategy to promote access to, and the success of, personalised medicine. To deliver on the promise of this new approach to treatment, there is an urgent need to solve the largest problems in clinical trials: patient recruitment and engagement. This is where Sano’s innovative software platform, which allows them to interact directly with patients, biotech and broader healthcare communities, can be transformational for the future of personalised medicine."

"We are thrilled with this new, exciting stage for Glaia. Many climate friendly technologies tackle the issue of emissions directly – but we decided to approach the problem from the other direction. What if we could improve current productivity without increasing the carbon footprint?"